Martin Horstmann

Prof. Martin Horstmann is a leading academic in pediatric hematology and oncology at the University Medical Center Hamburg-Eppendorf (UKE). He holds a professorship in the Department of Pediatric Hematology and Oncology within the Faculty of Medicine. His roles include Scientific Director of the Childhood Cancer Center Hamburg (Kinderkrebs-Zentrum Hamburg) and Study Director of the COALL clinical trials. He is also a senior physician specializing in pediatric hematology/oncology.

His research focuses on molecular mechanisms of pediatric leukemias, including genetic drivers, minimal residual disease (MRD) analysis, and translational applications of AI in diagnostics. Key areas include B-cell precursor ALL, T-cell ALL, and targeted therapies. His work bridges clinical trials (e.g., CoALL studies) with genomic insights, emphasizing risk stratification and precision medicine.

Publications from 2024 highlight advancements in AI-driven diagnostic frameworks, IKZF1 deletion prognostics, and signaling pathway modulation (e.g., Ikaros-AKT interactions). Earlier work (2023–2014) explores SHIP1 function in T-ALL, PAX5 mutations, and kinase inhibitor strategies. His team collaborates internationally, contributing to global pediatric leukemia treatment protocols.

Horstmann’s lab is part of the UKE’s comprehensive cancer research infrastructure, including the University Cancer Center Hamburg (UCCH) and translational platforms like the European Liquid Biopsy Society (ELBS). He advises on clinical protocols integrating pharmacogenomics and molecular diagnostics to improve outcomes for pediatric cancer patients.